CARs of the future
Open Access
- 25 January 2019
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 94 (S1) , S55-S58
Abstract
CAR T cells have revolutionized the treatment of relapsed and refractory CD19‐positive leukemia and lymphoma. Unfortunately, the majority of patients treated will not achieve durable remissions. Reasons for these suboptimal clinical outcomes can be tied back to intrinsic CAR T cell design and manufacturing processes, factors that are highly amenable to modification and improvement. As CAR T cell therapy is being deployed in spaces outside of CD19‐positive disease, these limitations, complications, and setbacks need to be overcome, allowing for the full potential of this novel therapy to be realized. Preclinical work has begun tackling these major roadblocks, paving the way for potentially off‐the‐shelf products that are safer and more potent. In time, a number of these advances will be translated to the clinic and usher in an era of CARs of the future.Keywords
This publication has 28 references indexed in Scilit:
- In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeEMBO Molecular Medicine, 2018
- Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaCancer Discovery, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonistsBlood Advances, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriersNature Nanotechnology, 2017
- Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T CellsMolecular Therapy, 2017
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature, 2017
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cellsScience Translational Medicine, 2017
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011